EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review

Takafumi Yanagisawa iD, Pawel Rajwa, Fahad Quhal iD, Tatsushi Kawada iD, Kensuke Bekku iD, Ekaterina Laukhtina iD, Markus von Deimling, Marcin Chlosta, Pierre I Karakiewicz, Takahiro Kimura iD, Shahrokh F Shariat

Journal of Personalized Medicine · 07.04.2023 · 13 (4) · 641

DOI: 10.3390/jpm13040641 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 07.04.2023. Verfasst von Takafumi Yanagisawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090 Vienna, Austria. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Several phase II studies, including randomized controlled trials (RCTs), assessed the efficacy of adding androgen receptor signaling inhibitors (ARSIs) to androgen deprivation therapy (ADT) as a neoadjuvant treatment in patients treated with radical prostatectomy (RP) for prostate cancer (PCa). Summarizing the early results of these studies could help in designing phase III trials and patient counseling. (2)

Methods

We queried three databases in January 2023 for studies that included PCa patients treated with neoadjuvant ARSI-based combination therapy before RP. The outcomes of interest were oncologic outcomes and pathologic responses, such as pathologic complete response (pCR) and minimal residual disease (MRD). (3)

Results

Overall, twenty studies (eight RCTs) were included in this systematic review. Compared to ADT or ARSI alone, ARSI + ADT was associated with higher pCR and MRD rates; this effect was less evident when adding a second ARSI or chemotherapy. Nevertheless, ARSI + ADT resulted in relatively low pCR rates (0–13%) with a high proportion of ypT3 (48–90%) in the resected specimen. PTEN loss, ERG positive, or intraductal carcinoma seem to be associated with worse pathologic response. One study that adjusted for the effects of possible confounders reported that neoadjuvant ARSI + ADT improved time to biochemical recurrence and metastasis-free survival compared to RP alone. (4)

Conclusions

Neoadjuvant ARSI + ADT combination therapy results in improved pathologic response compared to either alone or none in patients with non-metastatic advanced PCa. Ongoing phase III RCTs with long-term oncologic outcomes, as well as biomarker-guided studies, will clarify the indication, oncologic benefits, and adverse events of ARSI + ADT in patients with clinically and biologically aggressive PCa.

Schlagwörter

Stichwörter der Autor:innen

androgen receptor signaling inhibitorsneoadjuvant therapyprostate cancerradical prostatectomy

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090 Vienna, Austria.
  • Department of Urology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
  • Department of Urology, Medical University of Silesia, 41-800 Zabrze, Poland.
  • Department of Urology, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia.
  • Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8530, Japan.
  • Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia.

ORCID-Profile: Takafumi Yanagisawa, Fahad Quhal, Tatsushi Kawada, Kensuke Bekku, Ekaterina Laukhtina, Takahiro Kimura

Zitieren

APA

Yanagisawa, T., Rajwa, P., Quhal, F., Kawada, T., Bekku, K., Laukhtina, E., Deimling, M. V., Chlosta, M., Karakiewicz, P. I., Kimura, T., & Shariat, S. F. (2023). Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review. Journal of Personalized Medicine, 13(4), 641. https://doi.org/10.3390/jpm13040641

Vancouver

Yanagisawa T, Rajwa P, Quhal F, Kawada T, Bekku K, Laukhtina E, et al. Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review. Journal of Personalized Medicine. 2023;13(4):641. doi:10.3390/jpm13040641

BibTeX
@article{Yanagisawa2023,
  author = {Yanagisawa, Takafumi and Rajwa, Pawel and Quhal, Fahad and Kawada, Tatsushi and Bekku, Kensuke and Laukhtina, Ekaterina and Deimling, Markus von and Chlosta, Marcin and Karakiewicz, Pierre I and Kimura, Takahiro and Shariat, Shahrokh F},
  title = {Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {4},
  pages = {641},
  doi = {10.3390/jpm13040641}
}
Kostenlos starten →